XBI icon

SPDR S&P Biotech ETF

699 hedge funds and large institutions have $7.06B invested in SPDR S&P Biotech ETF in 2022 Q1 according to their latest regulatory filings, with 123 funds opening new positions, 242 increasing their positions, 185 reducing their positions, and 112 closing their positions.

Holders
699
Holders Change
+1
Holders Change %
+0.14%
% of All Funds
11.06%
Holding in Top 10
20
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.32%
New
123
Increased
242
Reduced
185
Closed
112
Calls
$2.67B
Puts
$2.59B
Net Calls
+$79M
Net Calls Change
+$799M
Name Market Value Shares Shares
Change
Shares
Change %
BSCM
826
Berry Street Capital Management
United Kingdom
AC
827
Antara Capital
New York
SCM
828
Soleus Capital Management
Connecticut
MCM
829
Masters Capital Management
Georgia
NCM
830
Nantahala Capital Management
Connecticut
SCM
831
Silverarc Capital Management
Massachusetts
HNB
832
Huntington National Bank
Ohio
CANY
833
Caxton Associates (New York)
New York
SPPAM
834
Summit Partners Public Asset Management
Massachusetts
Marshall Wace
835
Marshall Wace
United Kingdom
BM
836
Baymount Management
Florida
CHAM
837
Clear Harbor Asset Management
Connecticut
PCM
838
Prelude Capital Management
New York
IC
839
Ikarian Capital
Texas
PCM
840
Potomac Capital Management
New York
BCM
841
Bronte Capital Management
Australia
CL
842
CSS LLC
Illinois
WA
843
Win Advisors
Florida
DCM
844
Driehaus Capital Management
Illinois
BCPEMI
845
Bain Capital Public Equity Management II
Massachusetts
KSCM
846
Kamunting Street Capital Management
Florida
CA
847
CHI Advisors
New York
TMC
848
Trellus Management Company
Florida
Squarepoint
849
Squarepoint
New York
GTC
850
Ghost Tree Capital
New York